A large, randomized trial in China involving 720 adults with hypertension demonstrated that bedtime dosing of olmesartan-amlodipine significantly improved nocturnal blood pressure control without increasing adverse events. Administering the medication at night resulted in greater reductions in nighttime systolic blood pressure compared to morning dosing, with statistically significant outcomes after 12 weeks. The study also highlighted improved circadian rhythm and no added risks of nocturnal hypotension across various demographics. Limitations include the exclusive study population and the short duration of follow-up, but findings encourage further research on antihypertensive chronotherapy.

Source: JAMA Network Open